Psoriatic Arthritis at Risk for Interstitial Lung Disease Save
A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD).
A retrospective analysis of the TriNetX US database (2014–2024) analyzed adult patients with PsO or PsA treated with systemic immunosuppressive medications. Cohorts underwent propensity score matching (PSM) adjusted for age, sex, race, body mass index, smoking status, and medications known to cause ILD.
Among a total of 13,168 PsA patients, ILD was more common than the general population (n = 13,168) (RR 1.94; 95% CI 1.29–2.92; p = 0.0011). By contrast, PsO patients (n = 24,039) showed no significant difference in ILD risk compared with the general population (n = 23,786) (RR 0.79; 95% CI 0.57–1.08; p = 0.14).
PsA (n = 13,838) exhibited an over 1.5 times increase in ILD risk compared with PsO (n = 13,842) (RR 1.52).
Another comparative study from 5 Nordic registries looked at the risk of ILD in rheumatoid arthritis (RA) and PsA initiating bDMARD, and found the risk of ILD was higher in RA and PsA, compared to the general population, but was highest in RA. Methotrexate co-medication was not a risk determinant for ILD.
These data suggest a need for respiratory monitoring in PsA patients, in a manner similar to RA assessments.
More EULAR Coverage:
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.